Rivaroxaban 15 MG

DRUG8 trials

Conditions

AcidosisAcute Coronary SyndromeAnticoagulant Adverse ReactionAnticoagulants and Bleeding DisordersAtrial FibrillationBleedingCoronary Artery EctasiaEnd-Stage Renal Disease

Phase 1

A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis

CompletedNCT02289703

Janssen Research & Development, LLCEnd-Stage Renal Disease

Start: 2015-01-31End: 2015-03-31Updated: 2017-01-24

Phase 2

Rivaroxaban vs Warfarin in Patients With Metallic Prosthesis

TerminatedNCT03566303

Hospital Geral Roberto SantosAnticoagulants and Bleeding Disorders, Prostheses and Implants, Stroke +1

Start: 2018-07-10End: 2020-04-26Updated: 2020-05-15

Antithrombotic Therapy in Acute Coronary Syndromes and Coronary Artery Ectasia

NCT05233124

Instituto Nacional de Cardiologia Ignacio ChavezAcute Coronary Syndrome, Coronary Artery Ectasia

Start: 2021-09-01End: 2024-07-30Target: 60Updated: 2022-02-10

Phase 3

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

CompletedNCT01830543

Janssen Scientific Affairs, LLCAtrial Fibrillation, Percutaneous Coronary Intervention

Start: 2013-05-10End: 2016-07-28Updated: 2017-09-19

Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI

CompletedNCT05705089

Rajaie Cardiovascular Medical and Research CenterLeft Ventricular Thrombus, ST Segment Elevation Myocardial Infarction

Start: 2020-07-30End: 2023-04-01Updated: 2023-04-07

Phase 4

Efficacy and Safety of Rivaroxiban Compare With Vitamin K Antagonist Warfarin

WithdrawnNCT03673605

PharmEvo Pvt LtdAtrial Fibrillation, Mitral Valve Stenosis

Start: 2016-12-30End: 2017-12-30Updated: 2018-09-17

Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation

RecruitingNCT06187311

Korea University Anam HospitalAnticoagulant Adverse Reaction, Atrial Fibrillation

Start: 2023-01-12End: 2027-06-30Target: 940Updated: 2024-01-05

Unknown Phase

The Effects of Hypothermia and Acidosis on Coagulation During Treatment With Rivaroxaban Measured With ROTEM

CompletedNCT05669313

Thomas KanderAcidosis, Bleeding, Hypothermia +1

Start: 2022-09-04End: 2022-11-10Updated: 2023-03-01

2025-01-0112 citations

A randomized trial of antithrombotic therapy in patients with acute coronary syndrome and coronary ectasia.

2024-11-295 citations

Synergistic effects of rivaroxaban and hypothermia or acidosis on coagulation initiation measured with ROTEM®: a prospective observational study

Thrombosis Journal2024-10-18

Dual Antiplatelet Therapy Versus Antiplatelet Monotherapy Plus Oral Anticoagulation in Patients with Acute Coronary Syndrome and Coronary Artery Ectasia: Design and Rationale of OVER-TIME Randomized Clinical Trial.

2022-07-295 citations

Rivaroxaban Versus Warfarin in Patients with Mechanical Heart Valves: Open-Label, Proof-of-Concept trial-The RIWA study.

2020-11-0527 citations

Machine learning versus traditional risk stratification methods in acute coronary syndrome: a pooled randomized clinical trial analysis.

2020-01-0135 citations

Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation

Circulation Cardiovascular Interventions2019-11-013 citations

Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention

Circulation Cardiovascular Interventions2019-02-0111 citations

Rivaroxaban versus Warfarin in Patients with Mechanical Heart Valve: Rationale and Design of the RIWA Study.

2018-12-018 citations

Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention.

2018-10-0110 citations

Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.

2018-03-1424 citations

Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy

Circulation2016-11-1595 citations

Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI

New England Journal of Medicine2016-11-141525 citations

An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI).

2014-12-20102 citations